MONTREAL, QUEBEC--(Marketwire - October 03, 2007) - Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that it has concluded an agreement on the terms and conditions of an option to license the exclusive worldwide therapeutic and diagnostic rights on Clusterin-specific antibodies from the National Research Council Biotechnology Research Institute (NRC-BRI). Under the terms of the option agreement, Alethia obtains a family of high-affinity antibodies that block the function of secreted Clusterin to prevent tumor invasion. Alethia also gains access to the NRC-BRI’s expertise in the humanization and production of therapeutics antibodies which will accelerate the development of these monoclonals to the clinical stage.
